Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Director | September 11, 2026 | September 15, 2026 |
| Xencor IncXNCR · Entity 4487 | Director | June 16, 2026 | July 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROCRINE BIOSCIENCES INC
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 525,636 |
Reported balance
After 2026-09-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-11 · Grant · Acquired 14,343 · Balance 525,636 F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 517,797 |
Reported balance
After 2026-09-11 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-11 · Tax withholding · Disposed 7,839 · Balance 517,797 F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. F3: 517,797 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
F3: 517,797 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.
Xencor Inc
Report date June 16, 2026 · Filed July 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,680 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 10,302 · Balance 21,680 F1: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.20 · Expires 2036-06-15 | Direct | 20,604 |
Reported balance
After 2026-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-16 · Grant · Acquired 20,604 · Balance 20,604 F2: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 16, 2026, such that the total number of shares will be fully vested on June 16, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant.
F2: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 16, 2026, such that the total number of shares will be fully vested on June 16, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 15, 2026 21:05 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 7,839 | $156.22 | $1,224,608.58 |
DisclosureSEC source: 0001201096-26-000018 · wk-form4_1789506329.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 517,797 F2 · kind: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. F3 · balance_after: 517,797 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 21:05 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantCommon Stock | 14,343 | $0.00 | $0.00 |
DisclosureSEC source: 0001201096-26-000018 · wk-form4_1789506329.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 525,636 F1 · kind: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. Read SEC document |
| June 16, 2026 Filed Jul 8, 2026 22:54 UTC | Xencor Inc XNCR · Entity 4487 | GrantStock Option (Right to Buy) · Derivative | 20,604 | $0.00 Strike: $12.20 | $0.00 |
DisclosureSEC source: 0001201096-26-000016 · wk-form4_1783551296.xml · derivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,604 Underlying: Common Stock · 20,604 shares Expires 2036-06-15 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 16, 2026, such that the total number of shares will be fully vested on June 16, 2027. Read SEC document |
| June 16, 2026 Filed Jul 8, 2026 22:54 UTC | Xencor Inc XNCR · Entity 4487 | GrantCommon Stock | 10,302 | $0.00 | $0.00 |
DisclosureSEC source: 0001201096-26-000016 · wk-form4_1783551296.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,680 F1 · shares: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:02 UTC | Xencor Inc XNCR · Entity 4487 | SaleCommon Stock | 7,527 | $12.31 | $92,657.37 |
DisclosureSEC source: 0001201096-26-000014 · wk-form4_1781726521.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,378 F1 · kind: This transaction is pursuant to a 10b5-1 plan adopted by the Reporting Person on June 27, 2025. Read SEC document |
| May 27, 2026 Filed May 29, 2026 22:05 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantNon-Qualified Stock Option · Derivative | 5,248 | $0.00 Strike: $155.83 | $0.00 |
DisclosureSEC source: 0001201096-26-000012 · wk-form4_1780092347.xml · derivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,248 Underlying: Common Stock · 5,248 shares Expires 2036-05-27 F1 · derivative.exercise_date: Option vests in 12 monthly installments beginning June 27, 2026. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:49 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 205,088 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001201096-26-000010 · wk-form4_1779400189.xml · derivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 205,088 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017. These options were due to expire on February 6, 2027. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:49 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 245,088 | $154.33 | $37,824,872.20 |
DisclosureSEC source: 0001201096-26-000010 · wk-form4_1779400189.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 511,293 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $153.30 to $156.59. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: 511,293 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:49 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 205,088 | $43.24 | $8,868,005.12 |
DisclosureSEC source: 0001201096-26-000010 · wk-form4_1779400189.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 756,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 5,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001201096-26-000005 · wk-form4_1771368269.xml · derivative · entry 8 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,377 Underlying: Common Stock · 5,377 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 5,376 shares on February 13, 2024, vested as to 5,376 shares on February 13, 2025, vested as to 5,377 shares on February 13, 2026, and will vest as to 5,377 shares on February 13, 2027, subject to the terms and conditions of the award. F6 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 5,376 shares on February 13, 2024, vested as to 5,376 shares on February 13, 2025, vested as to 5,377 shares on February 13, 2026, and will vest as to 5,377 shares on February 13, 2027, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 5,604 | $0.00 | $0.00 |
DisclosureSEC source: 0001201096-26-000005 · wk-form4_1771368269.xml · derivative · entry 7 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,208 Underlying: Common Stock · 5,604 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 5,603 shares on February 13, 2025, vested as to 5,604 shares on February 13, 2026, and will vest as to 5,604 shares on February 13, 2027, and 5,604 shares on February 13, 2028, subject to the terms and conditions of the award. F5 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 5,603 shares on February 13, 2025, vested as to 5,604 shares on February 13, 2026, and will vest as to 5,604 shares on February 13, 2027, and 5,604 shares on February 13, 2028, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 34,380 | $124.12 | $4,267,245.60 |
DisclosureSEC source: 0001201096-26-000005 · wk-form4_1771368269.xml · nonDerivative · entry 6 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 551,293 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. F3 · balance_after: 551,293 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantCommon Stock | 63,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001201096-26-000005 · wk-form4_1771368269.xml · nonDerivative · entry 5 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 585,673 F2 · shares: On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 2,901 | $124.12 | $360,072.12 |
DisclosureSEC source: 0001201096-26-000005 · wk-form4_1771368269.xml · nonDerivative · entry 4 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 521,949 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 5,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001201096-26-000005 · wk-form4_1771368269.xml · nonDerivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 524,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 3,024 | $124.12 | $375,338.88 |
DisclosureSEC source: 0001201096-26-000005 · wk-form4_1771368269.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 519,473 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 5,604 | $0.00 | $0.00 |
DisclosureSEC source: 0001201096-26-000005 · wk-form4_1771368269.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 522,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 5,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001201096-26-000003 · wk-form4_1770159750.xml · derivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,142 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 5,141 shares on January 31, 2023, vested as to 5,141 shares on January 31, 2024, vested as to 5,141 shares on January 31, 2025, and vested as to 5,142 shares on January 31, 2026, subject to the terms and conditions of the award. F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 5,141 shares on January 31, 2023, vested as to 5,141 shares on January 31, 2024, vested as to 5,141 shares on January 31, 2025, and vested as to 5,142 shares on January 31, 2026, subject to the terms and conditions of the award. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 2,845 | $136.06 | $387,090.70 |
DisclosureSEC source: 0001201096-26-000003 · wk-form4_1770159750.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 516,893 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold. F2 · balance_after: 516,893 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 5,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001201096-26-000003 · wk-form4_1770159750.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 519,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 20:55 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 106,322 | $0.00 Strike: $35.99 | $0.00 |
DisclosureSEC source: 0000914475-25-000166 · wk-form4_1754945711.xml · derivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 106,322 shares Expires 2026-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning on March 5, 2016. These options were due to expire on February 5, 2026. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 20:55 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 106,322 | $126.41 | $13,440,280.97 |
DisclosureSEC source: 0000914475-25-000166 · wk-form4_1754945711.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 514,596 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $124.80 to $129.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range F3 · balance_after: 514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 20:55 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 106,322 | $35.99 | $3,826,528.78 |
DisclosureSEC source: 0000914475-25-000166 · wk-form4_1754945711.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 620,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2025 Filed Jun 16, 2025 23:30 UTC | Xencor Inc XNCR · Entity 4487 | SaleCommon Stock | 3,173 | $9.22 | $29,255.06 |
DisclosureSEC source: 0001127602-25-017597 · form4.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,905 F2 · kind: This transaction is pursuant to a 10b5-1 plan adopted by the Reporting Person on June 28, 2024. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 23:30 UTC | Xencor Inc XNCR · Entity 4487 | GrantStock Option (Right to Buy) · Derivative | 27,372 | $0.00 Strike: $9.43 | $0.00 |
DisclosureSEC source: 0001127602-25-017597 · form4.xml · derivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,372 Underlying: Common Stock · 27,372 shares Expires 2035-06-11 F3 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 12, 2025, such that the total number of shares will be fully vested on June 12, 2026. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 23:30 UTC | Xencor Inc XNCR · Entity 4487 | GrantCommon Stock | 13,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-017597 · form4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,078 F1 · shares: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant. Read SEC document |
| May 27, 2025 Filed May 29, 2025 22:15 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 9,613 | $120.38 | $1,157,211.02 |
DisclosureSEC source: 0000914475-25-000137 · wk-form4_1748556907.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 514,596 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2025. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $119.62 to $120.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: 514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:29 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantNon-Qualified Stock Option · Derivative | 6,610 | $0.00 Strike: $120.56 | $0.00 |
DisclosureSEC source: 0000914475-25-000132 · wk-form4_1747949388.xml · derivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,610 Underlying: Common Stock · 6,610 shares Expires 2035-05-21 F1 · derivative.exercise_date: Option vests in 12 monthly installments beginning June 21, 2025. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:57 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 5,603 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000073 · wk-form4_1739577443.xml · derivative · entry 6 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,812 Underlying: Common Stock · 5,603 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F8 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 5,603 shares on February 13, 2025, and will vest as to 5,604 shares on February 13, 2026, 5,604 shares on February 13, 2027, and 5,604 shares on February 13, 2028, subject to the terms and conditions of the award. F8 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 5,603 shares on February 13, 2025, and will vest as to 5,604 shares on February 13, 2026, 5,604 shares on February 13, 2027, and 5,604 shares on February 13, 2028, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:57 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 5,376 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000073 · wk-form4_1739577443.xml · derivative · entry 5 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,754 Underlying: Common Stock · 5,376 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F7 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 5,376 shares on February 13, 2024, vested as to 5,376 shares on February 13, 2025, and will vest as to 5,377 shares on February 13, 2026, and 5,377 shares on February 13, 2027, subject to the terms and conditions of the award. F7 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 5,376 shares on February 13, 2024, vested as to 5,376 shares on February 13, 2025, and will vest as to 5,377 shares on February 13, 2026, and 5,377 shares on February 13, 2027, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:57 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 3,012 | $116.68 | $351,449.80 |
DisclosureSEC source: 0000914475-25-000073 · wk-form4_1739577443.xml · nonDerivative · entry 4 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 524,209 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.02 to $117.32. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F5 · balance_after: 514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:57 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 5,603 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000073 · wk-form4_1739577443.xml · nonDerivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:57 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,832 | $116.69 | $330,464.66 |
DisclosureSEC source: 0000914475-25-000073 · wk-form4_1739577443.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 521,618 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.92 to $117.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:57 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 5,376 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000073 · wk-form4_1739577443.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 524,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 23:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,274 | $118.37 | $269,167.24 |
DisclosureSEC source: 0000914475-25-000052 · wk-form4_1739404561.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 519,074 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.06 to $123.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: 514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 23:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 4,318 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000052 · wk-form4_1739404561.xml · derivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,318 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 8, 2021. In accordance with the terms of the RSU, the award vested as to 4,317 shares on February 8, 2022, vested as to 4,317 shares on February 8, 2023, vested as to 4,317 shares on February 8, 2024, and vested as to 4,318 shares on February 8, 2025, subject to the terms and conditions of the award. F5 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 8, 2021. In accordance with the terms of the RSU, the award vested as to 4,317 shares on February 8, 2022, vested as to 4,317 shares on February 8, 2023, vested as to 4,317 shares on February 8, 2024, and vested as to 4,318 shares on February 8, 2025, subject to the terms and conditions of the award. Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 23:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 4,318 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000052 · wk-form4_1739404561.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 521,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 5,141 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000031 · wk-form4_1738709906.xml · derivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,142 Underlying: Common Stock · 5,141 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 5,141 shares on January 31, 2023, vested as to 5,141 shares on January 31, 2024, vested as to 5,141 shares on January 31, 2025, and will vest as to 5,142 shares on January 31, 2026, subject to the terms and conditions of the award. F5 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 5,141 shares on January 31, 2023, vested as to 5,141 shares on January 31, 2024, vested as to 5,141 shares on January 31, 2025, and will vest as to 5,142 shares on January 31, 2026, subject to the terms and conditions of the award. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,707 | $152.92 | $413,966.89 |
DisclosureSEC source: 0000914475-25-000031 · wk-form4_1738709906.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 517,030 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.85 to $154.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: 514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 5,141 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000031 · wk-form4_1738709906.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 519,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2025 Filed Jan 30, 2025 00:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 146,105 | $0.00 Strike: $32.99 | $0.00 |
DisclosureSEC source: 0000914475-25-000009 · wk-form4_1738195415.xml · derivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 146,105 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted February 3, 2015 and vested in 48 equal monthly installments beginning on March 3, 2015. These options were due to expire on February 3, 2025. Read SEC document |
| January 27, 2025 Filed Jan 30, 2025 00:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 146,105 | $149.46 | $21,836,502.65 |
DisclosureSEC source: 0000914475-25-000009 · wk-form4_1738195415.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 514,596 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $147.20 to $151.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: 514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. Read SEC document |
| January 27, 2025 Filed Jan 30, 2025 00:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 146,105 | $32.99 | $4,820,003.95 |
DisclosureSEC source: 0000914475-25-000009 · wk-form4_1738195415.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 660,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 20:09 UTC | Xencor Inc XNCR · Entity 4487 | SaleCommon Stock | 2,654 | $20.68 | $54,884.72 |
DisclosureSEC source: 0001127602-24-024672 · form4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,392 F1 · shares: Sale was pursuant to a 10b5-1 plan arranged to cover withholding taxes upon vesting of restricted stock units. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:22 UTC | Xencor Inc XNCR · Entity 4487 | GrantStock Option (Right to Buy) · Derivative | 11,971 | $0.00 Strike: $21.31 | $0.00 |
DisclosureSEC source: 0001127602-24-018831 · form4.xml · derivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,971 Underlying: Common Stock · 11,971 shares Expires 2034-06-12 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 13, 2024, such that the total number of shares will be fully vested on June 13, 2025. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:22 UTC | Xencor Inc XNCR · Entity 4487 | GrantCommon Stock | 5,986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-018831 · form4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,046 F1 · shares: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant. Read SEC document |
| February 13, 2024 Filed Feb 14, 2024 22:17 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionIncentive Stock Option · Derivative | 2,312 | $43.24 Strike: $43.24 | $99,970.88 |
DisclosureSEC source: 0000914475-24-000056 · wk-form4_1707948998.xml · derivative · entry 4 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,312 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017. Read SEC document |
| February 13, 2024 Filed Feb 14, 2024 22:17 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionIncentive Stock Option · Derivative | 2,778 | $35.99 Strike: $35.99 | $99,980.22 |
DisclosureSEC source: 0000914475-24-000056 · wk-form4_1707948998.xml · derivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,778 shares Expires 2026-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016. Read SEC document |
| February 13, 2024 Filed Feb 14, 2024 22:17 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,312 | $43.24 | $99,970.88 |
DisclosureSEC source: 0000914475-24-000056 · wk-form4_1707948998.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 512,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock. F2 · balance_after: 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. Read SEC document |
| February 13, 2024 Filed Feb 14, 2024 22:17 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,778 | $35.99 | $99,980.22 |
DisclosureSEC source: 0000914475-24-000056 · wk-form4_1707948998.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 509,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.